| Akcje zaległe | 77,187,823 shares |
| Akcje insidera | 27 921 493 shares |
| Własność insidera | 36,17 % |
| Insiderzy ogółem | 49 |
Wynik sentymentu insiderów
Ocena sentymentu insiderów pokazuje firmy, które są kupowane przez insiderów korporacyjnych.
Jest to wynik zaawansowanego, wieloczynnikowego modelu ilościowego, który identyfikuje spółki o najwyższym poziomie akumulacji informacji poufnych. Model rankingowy wykorzystuje kombinację liczby netto insiderów kupujących w ciągu ostatnich 90 dni, całkowitej liczby akcji kupionych jako procent akcji w obrocie oraz całkowitej liczby akcji posiadanych przez insiderów. Liczba ta waha się od 0 do 100, przy czym wyższe liczby wskazują na wyższy poziom akumulacji w porównaniu z innymi spółkami, a 50 to średnia.
Częstotliwość aktualizacji: codziennie
Ocena sentymentu kadry kierowniczej
Ocena sentymentu kadry kierowniczej pokazuje, że firmy są kupowane przez urzędników korporacyjnych.
Z definicji dyrektorzy korporacyjni to insiderzy korporacyjni, ale w przeciwieństwie do niektórych innych insiderów (10% akcjonariuszy i członków zarządu), dyrektorzy pracują dla firmy na co dzień i podczas handlu korzystają z własnych pieniędzy. (10% Akcjonariusze i członkowie zarządu często zarządzają funduszami zarządzających pieniędzmi innych osób). W związku z tym transakcje wykorzystujące informacje poufne dokonywane przez osoby z kadry kierowniczej mają znacznie większe znaczenie i powinny być odpowiednio traktowane.
Podobnie jak ocena sentymentu insiderów, ocena sentymentu kadry kierowniczej jest wynikiem zaawansowanego, wieloczynnikowego modelu ilościowego, który identyfikuje firmy o najwyższym poziomie akumulacji urzędników.
Częstotliwość aktualizacji: codziennie
Kluczowe wskaźniki insider
Ta karta pokazuje pozycję firmy według różnych wskaźników insider. Ranking według miary percentyla pokazuje, jak ta firma wypada na tle innych firm na rynkach amerykańskich. Wyższe rankingi wskazują na lepszą sytuację.
Na przykład ogólnie przyjmuje się, że kupowanie przez insiderów jest pozytywnym wskaźnikiem, zatem spółki z większą liczbą takich transakcji plasowałyby się wyżej niż spółki z mniejszą liczbą takich transakcji (lub nawet sprzedaży przez insiderów.
Liczba netto zakupów dokonanych przez insiderów (ranking)
2591 out of 10948
Liczba netto zakupów dokonanych przez insiderów to łączna liczba insiderów kupujących pomniejszona o całkowitą liczbę insiderów sprzedających w ciągu ostatnich 90 dni. Tutaj pokazana jest miara percentyla (zakres od 0 do 100%).
Procent akcji kupowanych przez insiderów (ranking)
2568 out of 10786
Procent akcji zakupionych przez insiderów to całkowita liczba akcji zakupionych przez insiderów pomniejszona o całkowitą liczbę akcji sprzedanych przez insiderów w ciągu ostatnich 90 dni, podzielona przez całkowitą liczbę akcji zakupionych przez insiderów i pomnożona przez 100.
Wykres handlu insider
Poniższy wykres przedstawia Eledon Pharmaceuticals, Inc. transakcji zrealizowanych przez insiderów. Insiderzy to członkowie kadry kierowniczej, dyrektorzy lub znaczący inwestorzy w spółce. Ogólnie rzecz biorąc, dokonywanie transakcji w ich firmach przez osoby posiadające dostęp do informacji poufnych w oparciu o istotne, niepubliczne informacje jest generalnie nielegalne. Nie oznacza to, że dokonywanie jakichkolwiek transakcji we własnych firmach jest nielegalne. Muszą jednak zgłaszać wszystkie transakcje do SEC za pośrednictwem formularza 4.
Lista insiderów i wskaźniki rentowności
Ta tabela przedstawia listę znanych insiderów i jest generowana automatycznie na podstawie zgłoszeń ujawnianych SEC. Oprócz nazwisk, najnowszego tytułu oraz oznaczenia dyrektora, członka kierownictwa lub 10% właściciela, podajemy najnowsze ujawnione pakiety akcji. Dodatkowo, jeśli to możliwe, udostępniamy historyczne wyniki handlowe danego insidera. Historyczne wyniki handlowe to średnia ważona wyników rzeczywistych transakcji zakupu na otwartym rynku dokonanych przez insiderów. Więcej informacji na temat sposobu obliczania tej wartości obejrzyj webinar na YouTube.
See our leaderboard of most profitable insider traders.
| Insider | Średni zysk (%) | Posiadane Akcje |
Podział korygujący |
|---|---|---|---|
|
Apple Tree Partners Ii Lp
Director, 10% Owner -
[D]
|
4 218 641 | 4 218 641 | |
|
Apple Tree Partners II - Annex, L.P.
Director, 10% Owner -
[D]
|
3 568 438 | 3 568 438 | |
|
Apple Tree Partners IV, L.P.
Director, 10% Owner -
[D]
|
250 000 | 250 000 | |
| Timothy J Barberich Director - [D] | 121 077 | 121 077 | |
| Biotechnology Value Fund Ii Lp - | 113 152 | 220 460 | |
| Biotechnology Value Fund L P - | 113 152 | 220 460 | |
|
Bvf Gp Holdings Llc
10% Owner -
|
113 152 | 220 460 | |
| Bvf I Gp Llc - | 113 152 | 220 460 | |
| Bvf Ii Gp Llc - | 113 152 | 220 460 | |
|
Bvf Inc/il
10% Owner -
|
113 152 | 220 460 | |
|
Bvf Partners L P/il
10% Owner -
|
220 460 | 220 460 | |
| BVF Partners OS Ltd. - | 113 152 | 220 460 | |
| Biotechnology Value Trading Fund OS LP - | 113 152 | 220 460 | |
| Buckley Stephen Jr. Director - [D] | 11 000 | 11 000 | |
| Erez Chimovits Director - [D] | 3 183 314 | 3 183 314 | |
| Cheryl Cohen Director - [D] | 0 | 0 |
| Insider | Średni zysk (%) | Posiadane Akcje |
Podział korygujący |
|---|---|---|---|
| Flesher Gregory J. Chief Executive Officer, Director - [D] [O] | 156 918 | 156 918 | |
| Karen Jean Ferrante | 62 000 | ||
| David-Alexandre C Gros Chief Executive Officer, Director - [D] [O] | 9 000 | 9 000 | |
|
Seth Loring Harrison
Director, 10% Owner -
[D]
|
7 912 079 | 7 912 079 | |
| Jan Hillson Director - [D] | 3 430 | 3 430 | |
| Lee Kalowski Chief Financial Officer - [O] | 40 953 | 40 953 | |
| Keith Katkin Director - [D] | 8 575 | 8 575 | |
| Kessler David A. | 12 000 | ||
| Allan Kirk Director - [D] | 3 430 | 3 430 | |
| Jon Kuwahara See Remarks - [O] | 5 974 | 5 974 | |
|
Mark N Lampert
10% Owner -
|
113 152 | 220 460 | |
|
Lifesci Index Partners Llc
10% Owner -
|
1 065 867 | 1 065 867 | |
| Gary A Lyons Director - [D] | 0 | 0 | |
| June Lee Director - [D] | 3 430 | 3 430 | |
| Paul Sean Little CHIEF FINANCIAL OFFICER - [O] | 10 000 | 10 000 | |
|
Logos Global Management LP
10% Owner -
|
224 071 | 224 071 |
| Insider | Średni zysk (%) | Posiadane Akcje |
Podział korygujący |
|---|---|---|---|
| McBride John S. Director - [D] | 3 430 | 3 430 | |
| Jodie Pope Morrison President and CEO, Director - [D] [O] | 57 566 | 57 566 | |
|
Ag Novartis
10% Owner -
|
4 493 458 | 4 493 458 | |
|
Bioventures Ltd Novartis
10% Owner -
|
4 493 458 | 4 493 458 | |
| Christine Ocampo See Remarks - [O] | 23 160 | 23 160 | |
| Walter C Ogier | 20 000 | ||
|
OrbiMed Israel BioFund GP Limited Partnership
Director, 10% Owner -
[D]
|
73 650 | 73 650 | |
|
OrbiMed Israel GP Ltd.
10% Owner -
|
73 650 | 73 650 | |
| Steven Perrin President, Director - [D] [O] | 1 000 | 1 000 | |
| Gerald E Quirk | 62 000 | ||
| Robinson James A. Jr. Director - [D] | 3 430 | 3 430 | |
|
Muneer A Satter
10% Owner -
|
1 771 688 | 1 771 688 | |
| Smith Bryan E. | 120 000 | ||
| Turkel Catherine C. President - [O] | 88 662 | 88 662 | |
|
Martin D Williams
10% Owner -
|
337 700 | 337 700 | |
|
Paul Yook
10% Owner -
|
1 065 867 | 1 065 867 | |
| Yanchik Joseph A., III Director - [D] | 51 092 | 51 092 |
Report errors via our new Insider Auditing Tool
Śledź historię zakupów insiderów — analiza zysków krótkoterminowych
W tej sekcji analizujemy rentowność każdego nieplanowanego zakupu od poufnych informacji na otwartym rynku dokonanego w ELDN / Eledon Pharmaceuticals, Inc.. Analiza ta pomaga zrozumieć, czy insider konsekwentnie generuje nietypowe zyski i czy warto ją śledzić. Analiza ta obejmuje okres jednego roku po każdej transakcji wyniki są teoretyczne .
Poniższa tabela przedstawia najnowsze zakupy na otwartym rynku, które nie były częścią planu handlu automatycznego.
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Śledź historię sprzedaży insider — analiza strat krótkoterminowych
W tej sekcji analizujemy możliwość uniknięcia krótkoterminowych strat w wyniku każdej nieplanowanej sprzedaży insidera na otwartym rynku dokonanej w ELDN / Eledon Pharmaceuticals, Inc.. Konsekwentny wzorzec unikania strat może sugerować, że przyszłe transakcje sprzedaży mogą przewidywać spadki cen. Analiza ta obejmuje okres jednego roku po każdej transakcji wyniki są teoretyczne .
Poniższa tabela przedstawia najnowsze sprzedaże na otwartym rynku, które nie były częścią planu handlu automatycznego.
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Historia transakcji
Kliknij ikonę linku, aby zobaczyć pełną historię transakcji. Transakcje zgłoszone w ramach automatycznego planu handlowego 10b5-1 będą oznaczone znakiem X w kolumnie oznaczonej 10b-5.
| Plik Data |
Data transakcji |
Formularz | Wtajemniczony | Serce | Nazwa papieru wartościowego | Kod | Bezpośredni | Cena wykonania |
Cena jednostki |
Zmieniono jednostki |
Zmieniona wartość (1 tys.) |
Pozostałe opcje |
Pozostałe akcje |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-16 | 2026-01-10 | 4 | Robinson James A. Jr. | ELDN | Common Stock | D | 3 430 | 3 430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Lee June | ELDN | Common Stock | D | 3 430 | 3 430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Katkin Keith | ELDN | Common Stock | D | 8 575 | 8 575 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Kirk Allan | ELDN | Common Stock | D | 3 430 | 3 430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Hillson Jan | ELDN | Common Stock | D | 3 430 | 3 430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | McBride John S. | ELDN | Common Stock | D | 3 430 | 3 430 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 75 431 | 220 460 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 821 121 | 2 633 679 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 1 031 385 | 3 361 803 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 86 341 | 145 029 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 837 146 | 1 812 558 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 1 055 445 | 2 330 418 | ||||||
| 2022-11-23 | 2022-11-23 | 4 | Perrin Steven | ELDN | Common Stock | D | 2,5969 | 1 000 | 3 | 1 000 | ||||
| 2022-02-02 | 2022-02-01 | 4 | Gros David-Alexandre C | ELDN | Stock Option (right to buy) | D | 3,97 | 108 000 | 108 000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Smith Bryan E. | ELDN | Stock Option (right to buy) | D | 3,97 | 120 000 | 120 000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Ogier Walter C | ELDN | Stock Option (right to buy) | D | 3,97 | 20 000 | 20 000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Perrin Steven | ELDN | Stock Option (right to buy) | D | 3,97 | 155 000 | 155 000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | McBride John S. | ELDN | Stock Option (right to buy) | D | 3,97 | 20 000 | 20 000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | LYONS GARY A | ELDN | Stock Option (right to buy) | D | 3,97 | 20 000 | 20 000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Lee June | ELDN | Stock Option (right to buy) | D | 3,97 | 20 000 | 20 000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Hillson Jan | ELDN | Stock Option (right to buy) | D | 3,97 | 20 000 | 20 000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Katkin Keith | ELDN | Stock Option (right to buy) | D | 3,97 | 20 000 | 20 000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Little Paul Sean | ELDN | Stock Option (right to buy) | D | 3,97 | 155 000 | 155 000 | |||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 975 412 | ||||||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 1 274 973 | ||||||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 58 688 | ||||||||
| 2021-12-21 | 2021-12-20 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 4,4800 | 2 000 | 9 | 9 000 | ||||
| 2021-08-19 | 2021-08-17 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 6,2100 | 4 000 | 25 | 7 000 | ||||
| 2021-06-14 | 2021-06-11 | 4 | Little Paul Sean | ELDN | Common Stock | D | 8,8700 | 10 000 | 89 | 10 000 | ||||
| 2021-06-10 | 2021-06-09 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 8,0100 | 3 000 | 24 | 3 000 | ||||
| 2021-05-04 | 2021-05-03 | 4 | Smith Bryan E. | ELDN | Stock Option (Right to Buy) | D | 9,91 | 158 500 | 158 500 | |||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -1 757 | 6 758 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -9 169 | 39 693 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -11 776 | 52 145 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -35 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -203 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -273 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 97 615 | 113 152 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 1 944 | 15 537 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 509 410 | 598 624 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 11 278 | 89 214 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 654 215 | 771 780 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 15 166 | 117 565 | ||||||
| 2020-12-04 | 2020-12-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 21,6000 | -103 200 | -2 229 | 73 650 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25,5507 | 9 098 | 232 | 224 071 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26,1740 | 15 000 | 393 | 214 973 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 27,0200 | -27 | -1 | 199 973 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25,8790 | 12 942 | 335 | 200 000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26,6442 | -12 942 | -345 | 187 058 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26,4824 | 15 000 | 397 | 200 000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25,9730 | 4 000 | 104 | 185 000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 24,5299 | 31 000 | 760 | 181 000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 24,0325 | 5 000 | 120 | 150 000 | ||||
| 2020-11-06 | 3 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 145 000 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 77 936 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 102 400 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 13 595 | ||||||||
| 2020-09-15 | 2020-09-11 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 500,00 | 1 167 | 1 167 | |||||
| 2020-09-15 | 2020-09-11 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 500,00 | 1 167 | 1 167 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 500,00 | 2 145 | 2 145 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 500,00 | 5 907 | 5 907 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Gros David-Alexandre C | NVUS | Stock Option (Right to Buy) | D | 500,00 | 18 278 | 18 278 | |||||
| 2020-03-20 | 2020-03-19 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 0,26 | 50 000 | 50 000 | |||||
| 2020-03-20 | 2020-03-19 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 0,26 | 100 000 | 100 000 | |||||
| 2020-03-20 | 2020-03-19 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 0,26 | 200 000 | 200 000 | |||||
| 2020-02-25 | 2020-01-14 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646 204 | 129 | 0 | ||||
| 2020-02-25 | 2020-01-14 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646 204 | 129 | 0 | ||||
| 2020-02-25 | 2020-01-14 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646 204 | 129 | |||||
| 2020-02-25 | 2020-01-14 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646 204 | 129 | |||||
| 2019-09-30 | 2019-09-26 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 0,67 | 100 000 | 100 000 | |||||
| 2019-09-30 | 2019-09-26 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 0,67 | 75 000 | 75 000 | |||||
| 2019-09-30 | 2019-09-26 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 0,67 | 60 000 | 60 000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Chimovits Erez | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20 000 | 20 000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20 000 | 20 000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20 000 | 20 000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20 000 | 20 000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20 000 | 20 000 | |||||
| 2019-05-22 | 2019-05-21 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 1,9114 | -2 937 | -6 | 156 918 | ||||
| 2019-05-22 | 2019-05-20 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 1,9616 | -11 701 | -23 | 159 855 | ||||
| 2019-05-22 | 2019-05-21 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 1,9114 | -1 058 | -2 | 5 974 | ||||
| 2019-05-22 | 2019-05-20 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 1,9616 | -4 218 | -8 | 7 032 | ||||
| 2019-05-22 | 2019-05-21 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 1,9114 | -1 914 | -4 | 88 662 | ||||
| 2019-05-22 | 2019-05-20 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 1,9616 | -7 623 | -15 | 90 576 | ||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646 204 | 646 204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646 204 | 646 204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez | NVUS | Common Stock | I | 3,1000 | 646 204 | 2 003 | 3 183 314 | ||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646 204 | 646 204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646 204 | 646 204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 3,1000 | 646 204 | 2 003 | 3 183 314 | ||||
| 2019-05-02 | 2019-04-30 | 4 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, par value $0.01 per share | I | 2,7000 | -200 | -1 | 1 065 867 | ||||
| 2019-03-18 | 2019-03-14 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 3,72 | 25 000 | 25 000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 3,72 | 90 000 | 90 000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 25 000 | 171 556 | ||||||
| 2019-03-18 | 2019-03-14 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 3,72 | 50 000 | 50 000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 20 000 | 98 199 | ||||||
| 2018-09-13 | 2018-09-12 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 5,0190 | 16 632 | 83 | 78 199 | ||||
| 2018-09-13 | 2018-09-11 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 4,5560 | 17 048 | 78 | 61 567 | ||||
| 2018-09-07 | 2018-09-05 | 4 | TURKEL CATHERINE C. By Spouse's IRA | NVUS | Common Stock | I | 3,9660 | 805 | 3 | 805 | ||||
| 2018-06-14 | 2018-06-13 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9 100 | 9 100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9 100 | 9 100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9 100 | 9 100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9 100 | 9 100 | |||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2 132 134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2 132 134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2 132 134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2 132 134 | ||||||||
| 2018-03-15 | 2018-03-13 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 4,83 | 24 000 | 24 000 | |||||
| 2018-03-15 | 2018-03-13 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 20 000 | 44 519 | ||||||
| 2018-03-15 | 2018-03-13 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 4,83 | 56 500 | 56 500 | |||||
| 2018-03-15 | 2018-03-13 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 30 700 | 146 556 | ||||||
| 2018-03-15 | 2018-03-13 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 4,83 | 12 000 | 12 000 | |||||
| 2018-03-15 | 2018-03-13 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 11 250 | 11 250 | ||||||
| 2017-11-06 | 2017-11-06 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 4,21 | 50 000 | 50 000 | |||||
| 2017-07-10 | 2017-07-10 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 5,61 | 35 000 | 35 000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 5,85 | 36 000 | 36 000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Morrison Jodie Pope | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18 000 | 18 000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18 000 | 18 000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18 000 | 18 000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18 000 | 18 000 | |||||
| 2017-05-26 | 2017-05-24 | 4 | OCAMPO CHRISTINE | NVUS | Stock Option (Right to Buy) | D | 5,50 | 52 500 | 52 500 | |||||
| 2017-05-26 | 2017-05-24 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 5,50 | 52 500 | 52 500 | |||||
| 2017-05-26 | 2017-05-24 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 5,50 | 250 000 | 250 000 | |||||
| 2017-05-11 | 3 | LYONS GARY A | NVUS | No Securities Owned | D | 0 | ||||||||
| 2017-05-11 | 3 | FLESHER GREGORY J. | NVUS | Common Stock | D | 113 794 | ||||||||
| 2017-05-11 | 3 | FLESHER GREGORY J. | NVUS | Common Stock | D | 113 794 | ||||||||
| 2017-05-11 | 3 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 26 816 | ||||||||
| 2017-05-11 | 3 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 26 816 | ||||||||
| 2017-05-11 | 3 | Katkin Keith | NVUS | Common Stock | D | 24 238 | ||||||||
| 2017-05-11 | 3 | Katkin Keith | NVUS | Common Stock | D | 24 238 | ||||||||
| 2017-05-11 | 3 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 23 160 | ||||||||
| 2017-05-11 | 3 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 23 160 | ||||||||
| 2017-05-11 | 3 | Chimovits Erez By OrbiMed Israel GP Ltd. | NVUS | Common Stock | I | 5 074 220 | ||||||||
| 2017-05-11 | 3 | Chimovits Erez By OrbiMed Israel GP Ltd. | NVUS | Common Stock | I | 5 074 220 | ||||||||
| 2017-05-11 | 2017-05-10 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 9,9900 | 58 959 | 589 | 115 856 | ||||
| 2017-05-11 | 2017-05-10 | 4 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 9,9900 | 10 010 | 100 | 21 590 | ||||
| 2017-05-11 | 2017-05-10 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 9,9900 | 11 111 | 111 | 24 519 | ||||
| 2017-05-11 | 2017-05-09 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 2 537 110 | 2 537 110 | ||||||
| 2016-06-16 | 2016-06-15 | 4 | BARBERICH TIMOTHY J | TKAI | Stock Option (right to buy) | D | 6,29 | 12 000 | 12 000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Harrison Seth Loring | TKAI | Stock Option (right to buy) | D | 6,29 | 12 000 | 12 000 | |||||
| 2016-06-16 | 2016-06-16 | 4 | Cohen Cheryl | TKAI | Stock Option (right to buy) | D | 6,29 | 12 000 | 12 000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 6,29 | 12 000 | 12 000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Yanchik Joseph A., III | TKAI | Stock Option (right to buy) | D | 6,29 | 12 000 | 12 000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Kessler David A. | TKAI | Stock Option (right to buy) | D | 6,29 | 12 000 | 12 000 | |||||
| 2016-03-15 | 2016-03-15 | 4 | Buckley Stephen Jr. | TKAI | Common Stock | D | 5,7400 | 8 000 | 46 | 11 000 | ||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,37 | -20 000 | 37 878 | |||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0,63 | -8 015 | 0 | |||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,3700 | 20 000 | 27 | 57 566 | ||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0,6300 | 8 015 | 5 | 37 566 | ||||
| 2015-12-17 | 2015-12-15 | 4 | Ferrante Karen Jean | TKAI | Stock Option (right to buy) | D | 9,65 | 62 000 | 62 000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 9,65 | 189 000 | 189 000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Kalowski Lee | TKAI | Stock Option (right to buy) | D | 9,65 | 62 000 | 62 000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 9,65 | 62 000 | 62 000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Quirk Gerald E | TKAI | Stock Option (right to buy) | D | 9,65 | 62 000 | 62 000 | |||||
| 2015-11-12 | 2015-11-11 | 4 | Buckley Stephen Jr. | TKAI | Common Stock | D | 11,2500 | 3 000 | 34 | 3 000 | ||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -13 500 | 186 678 | |||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Common Stock | D | 14,0100 | -13 500 | -189 | 0 | ||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 13 500 | 57 | 13 500 | ||||
| 2015-09-08 | 2015-09-08 | 4 | Kalowski Lee | TKAI | Common Stock | D | 13,1300 | -4 668 | -61 | 40 953 | ||||
| 2015-09-04 | 2015-09-02 | 4 | Kalowski Lee | TKAI | Common Stock | D | 12,9600 | -2 158 | -28 | 45 621 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,37 | -3 000 | 57 878 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0,63 | -7 000 | 8 015 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -564 | 312 736 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,3700 | 3 000 | 4 | 29 551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0,6300 | 7 000 | 4 | 26 551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,7000 | -564 | -8 | 19 551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 564 | 1 | 20 115 | ||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -12 000 | 313 300 | |||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,7000 | -12 000 | -164 | 19 551 | ||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 12 000 | 19 | 31 551 | ||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0,63 | -7 426 | 15 015 | |||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 2,31 | -2 574 | 0 | |||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0,6300 | 7 426 | 5 | 19 551 | ||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 2,3100 | 2 574 | 6 | 12 125 | ||||
| 2015-07-17 | 2015-07-15 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2580 | -3 566 | -51 | 4 493 458 | ||||
| 2015-07-15 | 2015-07-14 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,4100 | -27 861 | -401 | 4 497 024 | ||||
| 2015-07-15 | 2015-07-13 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2020 | -20 611 | -293 | 4 524 885 | ||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -8 000 | 325 300 | |||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,7000 | -8 000 | -110 | 9 551 | ||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 8 000 | 13 | 17 551 | ||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -8 000 | 333 300 | |||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,8300 | -8 000 | -111 | 9 551 | ||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 8 000 | 13 | 17 551 | ||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -300 | 200 178 | |||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Common Stock | D | 14,2000 | -300 | -4 | 0 | ||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 300 | 1 | 300 | ||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -6 700 | 200 478 | |||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Common Stock | D | 14,0000 | -6 700 | -94 | 0 | ||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 6 700 | 28 | 6 700 | ||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -2 000 | 207 178 | |||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Common Stock | D | 14,0200 | -2 000 | -28 | 0 | ||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 2 000 | 8 | 2 000 | ||||
| 2015-06-19 | 2015-06-17 | 4 | BARBERICH TIMOTHY J | TKAI | Stock Option (right to buy) | D | 14,04 | 12 000 | 12 000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Harrison Seth Loring | TKAI | Stock Option (right to buy) | D | 14,04 | 12 000 | 12 000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 14,04 | 12 000 | 12 000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Yanchik Joseph A., III | TKAI | Stock Option (right to buy) | D | 14,04 | 12 000 | 12 000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Kessler David A. | TKAI | Stock Option (right to buy) | D | 14,04 | 12 000 | 12 000 | |||||
| 2015-06-18 | 2015-06-16 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2700 | -1 120 | -16 | 4 545 496 | ||||
| 2015-06-16 | 2015-06-12 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2000 | -5 919 | -84 | 4 561 393 | ||||
| 2015-06-16 | 2014-06-15 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2000 | -14 777 | -210 | 4 546 616 | ||||
| 2015-06-12 | 2015-06-11 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2000 | -27 875 | -396 | 4 567 312 | ||||
| 2015-05-28 | 2015-05-26 | 4 | Quirk Gerald E | TKAI | Stock Option (right to buy) | D | 10,81 | 214 605 | 214 605 | |||||
| 2015-04-20 | 2015-04-16 | 4 | Kalowski Lee | TKAI | Common Stock | D | 13,0000 | -4 567 | -59 | 47 779 | ||||
| 2015-04-13 | 3 | Cohen Cheryl | TKAI | No securities are beneficially owned | D | 0 | ||||||||
| 2015-04-13 | 2015-04-09 | 4 | Cohen Cheryl | TKAI | Stock Option (right to buy) | D | 11,08 | 25 000 | 25 000 | |||||
| 2015-04-06 | 2015-04-02 | 4 | Kalowski Lee | TKAI | Common Stock | D | 11,4500 | -2 258 | -26 | 52 346 | ||||
| 2015-03-20 | 2015-03-19 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,5000 | -46 141 | -669 | 4 595 187 | ||||
| 2015-03-20 | 2015-03-18 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,5000 | -3 000 | -44 | 4 641 328 | ||||
| 2015-01-12 | 3 | Buckley Stephen Jr. | TKAI | No securities are beneficially owned | D | 0 | ||||||||
| 2015-01-12 | 2015-01-08 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 14,49 | 25 000 | 25 000 | |||||
| 2014-10-17 | 2014-10-15 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 13,25 | 134 134 | 134 134 | |||||
| 2014-10-17 | 2014-10-15 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 13,25 | 50 671 | 50 671 | |||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series E Preferred Stock | I | -8 013 003 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-3 Preferred Stock | I | -3 931 085 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-2 Preferred Stock | I | -457 728 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-1 Preferred Stock | I | -4 577 315 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Common Stock | I | 15,0000 | 150 000 | 2 250 | 1 771 688 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Common Stock | I | 1 621 688 | 1 621 688 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series E Preferred Stock | I | -24 199 308 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-3 Preferred Stock | I | -24 046 035 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-2 Preferred Stock | I | -1 539 643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-1 Preferred Stock | I | -8 711 335 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series C Preferred Stock | I | -14 604 833 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series B-2 Preferred Stock | I | -644 786 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series B-1 Preferred Stock | I | -798 067 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series A Preferred Stock | I | -4 500 000 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 15,0000 | 362 500 | 5 438 | 7 912 079 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 7 549 570 | 7 549 579 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Series E Preferred Stock | D | -24 199 308 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Series D-3 Preferred Stock | D | -10 675 613 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Common Stock | D | 15,0000 | 237 500 | 3 562 | 3 568 438 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Common Stock | D | 3 330 938 | 3 330 938 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | 165 251 | 165 251 | |||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series E Preferred Stock | D | -15 064 469 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-3 Preferred Stock | D | -13 222 826 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-2 Preferred Stock | D | -1 539 643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-1 Preferred Stock | D | -15 396 431 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 15,0000 | 325 000 | 4 875 | 4 644 328 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 4 319 328 | 4 319 328 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Series E Preferred Stock | D | -809 955 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Series D-3 Preferred Stock | D | -457 731 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Common Stock | D | 121 077 | 121 077 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-3 Preferred Stock | D | -13 370 422 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-2 Preferred Stock | D | -1 539 643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-1 Preferred Stock | D | -8 711 335 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series C Preferred Stock | D | -14 604 833 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series B-2 Preferred Stock | D | -644 786 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series B-1 Preferred Stock | D | -798 067 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series A Preferred Stock | D | -4 500 000 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 4 218 632 | 4 218 641 | ||||||
| 2014-09-24 | 3 | Apple Tree Partners IV, L.P. | TKAI | Common Stock | D | 250 000 | ||||||||
| 2014-09-24 | 3 | Apple Tree Partners IV, L.P. | TKAI | Common Stock | D | 250 000 | ||||||||
| 2014-09-18 | 2014-09-17 | 4 | Kalowski Lee | TKAI | Stock Option (right to buy) | D | 15,00 | 218 417 | 218 417 | |||||
| 2014-09-18 | 2014-09-17 | 4 | Kalowski Lee | TKAI | Common Stock | D | 54 604 | 54 604 | ||||||
| 2014-09-16 | 3 | Morrison Jodie Pope | TKAI | Common Stock | D | 19 102 | ||||||||
| 2014-09-16 | 3 | Morrison Jodie Pope | TKAI | Common Stock | D | 19 102 | ||||||||
| 2014-09-16 | 3 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 18 | ||||||||
| 2014-09-16 | 3 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 18 | ||||||||
| 2014-09-16 | 3 | Yanchik Joseph A., III | TKAI | Common Stock | D | 51 092 | ||||||||
| 2014-09-16 | 3 | Yanchik Joseph A., III | TKAI | Common Stock | D | 51 092 | ||||||||
| 2014-09-16 | 3 | Williams Martin D | TKAI | Common Stock | D | 337 700 | ||||||||
| 2014-09-16 | 3 | Williams Martin D | TKAI | Common Stock | D | 337 700 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 212 712 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring | TKAI | Common Stock | D | 425 397 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 212 712 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring | TKAI | Common Stock | D | 425 397 |
P
Otwarty rynek lub prywatny zakup niepochodnych lub pochodnych papierów wartościowych
S
Otwarty rynek lub prywatna sprzedaż niepochodnych lub pochodnych papierów wartościowych
A
Grant, nagroda lub inne nabycie papierów wartościowych od spółki (np. opcja)
C
Konwersja instrumentu pochodnego
D
Sprzedaż lub przeniesienie papierów wartościowych z powrotem do spółki
F
Zapłata ceny wykonania lub zobowiązania podatkowego z wykorzystaniem części papierów wartościowych otrzymanych od spółki
G
Darowizna papierów wartościowych przez lub na rzecz insidera
K
Swapy kapitałowe i podobne transakcje zabezpieczające
M
Wykonanie lub konwersja pochodnego papieru wartościowego otrzymanego od spółki (takiego jak opcja)
V
Transakcja dobrowolnie zgłoszona na Formularzu 4
J
Inne (wraz z przypisem opisującym transakcję)
